Genmab lands HC Wainwright buy reiteration, shares trade near NASDAQ range
24.06.2026 - 09:18:22 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 09:14.
Genmab (DK0010272202) drew fresh analyst attention this week. HC Wainwright & Co. has reiterated its Buy rating and a 38 dollar price target on the NASDAQ-listed biotech, adding a clear consensus marker for the GMAB shares. HC Wainwright update via GuruFocus
What HC Wainwright says
On June 23, 2026, HC Wainwright & Co. maintained its Buy rating for Genmab and kept the 38 dollar price target unchanged, after a recent adjustment from 40 dollars earlier in the year. Analyst note summary Analyst Raghuram Selvaraju continues to highlight Genmab's growth potential and competitive position in oncology and immunology. GuruFocus analyst coverage
Consensus picture and trading levels
GuruFocus cites a GF Value metric of 35.19 dollars for Genmab, compared with a current price of about 25.61 dollars, implying a roughly 27 percent discount versus the modelled fair value. GF Value data Technical data from TradingKey show GMAB around 25.94 dollars at the June 23 close, with the shares trading between a support level at 23.99 dollars and resistance near 27.51 dollars. TradingKey technical overview
All news and data on the Genmab shares
Further company disclosures, price data and background on Genmab are available in the dedicated topic section and via the official Investor Relations page.
The product behind the stock
Genmab's current portfolio includes epcoritamab, a bispecific antibody targeting CD3 and CD20 for B-cell malignancies. Recent company communications highlighted high response rates for epcoritamab-based regimens in elderly patients with newly diagnosed diffuse large B-cell lymphoma, underlining the clinical ambition in hematology. Finanzen100 summary of Genmab news
Where the stock trades today
Genmab shares (DK0010272202) last traded on NASDAQ on June 23, 2026, at around 25.94 dollars at 16:00 ET, while the German listing in Frankfurt showed bid and ask quotes near 226.40 and 228.30 euros respectively at the most recent update. NASDAQ GMAB quote
Genmab at a glance
- Company: Genmab A/S
- ISIN: DK0010272202
- WKN: 565131
- Ticker: GMAB
- Trading venue: NASDAQ, Frankfurt
- Price (as of 2026-06-23, 16:00): 25.94 USD
- Market cap: 16.22 billion USD (as of 2026-06-23)
- Sector / industry: Biotechnology & Medical Research
- Index membership: not in a major blue-chip index
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. All data are based on sources believed to be reliable but cannot be guaranteed.
